Radboud university medical center
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen
The Netherlands
Internal postal code 392
Philips van Leydenlaan 15
Radboudumc entrance west, route 392
T +31 24 366 83 33

Manager Policy, Quality and Support
mrs. J.A.H. Droste, PhD
rtcclinicalstudies@radboudumc.nl
www.radboudumc.nl

Dutch Chamber of Commerce
trade register 80262783

392
European Medicines Agency
Domenico Scarlattilaan 6,
1083 HS Amsterdam

Date	Our reference	Page
30 June 2022	AN/GR	1 of 1
Your reference	Contact	
	RTC Clinical Studies	

Subject
Results posting of 2007-001089-33: "Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ischemia-reperfusion injury in man"

Dear EMA,

On behalf of the Prof. dr. G.A.P.J.M. Rongen as the 2nd Sponsor of this study, I hereby confirm that the screening and inclusion of subjects in the following clinical trial protocol: "Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ischemia-reperfusion injury in man" with EudraCT number 2007-001089-33 (favourable Ethics Committee opinion on Sep 23rd 2008), **has never started**.

The reason for this is that the study product, Annexin A5, which was required to measure the primary study outcome, **did not come available**.

The Declaration End of Trial Form B7 reported "Completed", but this should be "**Prematurely Ended**".

We hope this information is satisfactory to finalize results posting.

With kind regards,

Arjan Nooteboom,
Research Consultant at RTC Clinical Studies
Radboudumc
rtcclinicalstudies@radboudumc.nl

cc Prof.dr. G.A.P.J.M Rongen